艾迪联合FOLFIRI方案治疗晚期结直肠癌患者的疗效研究

Clinical effect of Aidi injection combined with FOLFIRI program in treatment of advanced colorectal cancer

目的研究艾迪注射液联合FOLFIRI方案治疗晚期结直肠癌患者的临床疗效及对患者生活质量的影响,探索更有利于提高晚期结直肠癌患者疗效及生活质量的治疗方案。方法将120例晚期结直肠癌患者根据随机数字表法分为观察组和对照组,每组60例,对照组给予单纯FOLFIRI化疗方案治疗,予伊立替康(CPT-11,40 mg/支),180 mg/m2,第1天,静脉滴注;亚叶酸钙(LV),200 mg/m2,第1天,静脉滴注;氟尿嘧啶(5-Fu),600 mg/m2,静脉滴注,第1天;观察组在FOLFIRI化疗方案的基础上加用艾迪注射液100 ml以0.9%氯化钠注射液500 ml稀释后静脉滴注,1次/d。每14 d为一个周期,连续治疗4个周期后比较2组患者的近期疗效、生活质量。结果观察组患者的有效率为45.00%,对照组为40.00%,疾病控制率(DCR)为76.67%,对照组为73.33%,差异无统计学意义(χ2=0.43,0.32,P>0.05);观察组患者治疗后的KPS评分为84.12±6.73,明显高于对照组的75.23±6.52,差异具有统计学意义(t=4.12,P<0.05);观察组患者骨髓抑制的发生率为35.00%明显低于对照组的51.67%,差异具有统计学意义(χ2=4.79,P<0.05)。结论艾迪注射液联合FOLFIRI方案化疗用于治疗晚期结直肠癌疗效较好,并能显著提高患者的生活质量,值得在临床推广应用。

Objective To investigate the clinical effect of Aidi injection combined with FOLFIRI program in treatment of advanced colorectal cancer and its impact on quality of life of patients, andexplorea more effectivetreatment programto improve the quality of life of patients withadvanced colonandrectal cancer. Methods One hundred and twenty cases of patients with advanced colorectal cancer patients were randomly divided into the observation group and the control group with 60 cases in each group, and the control group was received FOLFIRI chemotherapy regimen alone, irinotecan （CPT-11,40 mg/ampoule, 180 mg/m2 support）, the first day, intravenous drip ; calcium folinate （LV） ,200 mg/m2, the first day, intra- venous drip; fluorouracil （5-Fu） ,600 mg/m2 ,intravenous drip,the first day. The observation group was given eddie 100 ml on basis of FOLFIRI, using O. 9% Sodium Chloride Injection diluted 500 mlintravenous drip, 1 time a day, Fourteen days as a cycle, with four cycles of treatment, the short-term efficacy, quality of life were compare between the two groups. Results A total of 120 patients with advanced colorectal cancer were randomly divided into observation group and control group with 60 cases in each group. The control group received FOLFIRI chemotherapy regimen alone, while the observation group received additional Aidi 100ml on basis of FOLFIRI. Fourteen days was a course, all patients received four courses of treatment. The short-term efficacy and QOL of patients were compared between the two groups. Conclusion The effective rate of the observation group was 45. 00%, the control groupwas 40. 00% ;disease control rate （DCR） of the observation group was 76. 67% ,the control group was 73.33% ,there was no statistically significant differ- ence （ χ2 = 0. 43,0.32, P 〉 0.05 ） ; After thetreatment, the KPS score （ 84. 12 ± 6.73 ） of the observation group was signifi- candy higher than（75.23 ±6. 52） of the control group,the difference was statistically significant（t=4. 12,P 〈0. 05） ; the myelosuppression incidence of the observation group was 35. 00%, significantly lower than 51.67% of the control group, the difference was statistically significant （ χ2 = 4. 79, P 〈 0. 05 ）.